Keytruda, also known as pembrolizumab, accounts for the bulk of the Rahway, New Jersey-based pharmaceutical giant's revenue. However, with its U.S. patent exclusivity ending in 2028, Merck (NYSE ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...

Merck, Cardiff Oncology, and others. . Key Metastatic Colorectal Cancer Therapies: Adagrasib (MRTX849) + cetuximab, MK-4280A (favezelimab and pembrolizumab), Lynparza (olaparib) ± bevacizumab ...